Mitapivat (also known as MK-7264) is a new anticoagulant medication used to reduce the risk of stroke in people with atrial fibrillation (a type of irregular heartbeat). It works by preventing blood clots from forming in the heart. Mitapivat is a direct oral anticoagulant (DOAC), meaning it works directly on the clotting proteins in the blood to prevent clot formation. It is taken as a once-daily tablet and does not require regular monitoring or dose adjustment. Common side effects include headache, diarrhea, and fatigue. Serious side effects are rare but can include bleeding and allergic reactions.
Mitapivat, sold under the brand name Pyrukynd, is a medication specifically designed to treat hemolytic anemia in adults with a deficiency in pyruvate kinase (PK).
Here's a breakdown of how Mitapivat works:
- Disease Target: Hemolytic anemia is a condition where red blood cells are destroyed faster than they can be produced by the body. In PK deficiency, the lack of functional pyruvate kinase enzyme disrupts energy production within red blood cells, leading to their premature breakdown and anemia.
- Mechanism of Action: Mitapivat belongs to a class of drugs called pyruvate kinase activators. It works by directly increasing the activity of the remaining pyruvate kinase enzyme, even if it's a mutant form. This helps red blood cells produce more energy, improve their survival, and ultimately reduce hemolytic anemia.
Key Points Regarding Mitapivat:
- First-in-Class Medication: Mitapivat is considered a novel, first-in-class treatment for PK deficiency-related hemolytic anemia.
- Dosage and Form: Mitapivat comes in tablet form and is typically taken orally. The exact dosage will be determined by a doctor based on your individual needs.
- Not a Cure: It's important to understand that Mitapivat manages hemolytic anemia caused by PK deficiency but doesn't cure the underlying condition. Consistent use is necessary to maintain its benefits.
- Potential Side Effects: Decreased estrogen levels in men, increased uric acid levels, back pain, and joint stiffness are some reported side effects.
Additional Information:
- Mitapivat is a relatively new medication, approved by the US Food and Drug Administration (FDA) in February 2022 and the European Union in November 2022.
- Research suggests it may also hold promise for treating other types of hemolytic anemia beyond PK deficiency.